ixekizumab
Selected indexed studies
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (N Engl J Med, 2016) [PMID:27299809]
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (Drugs Today (Barc), 2023) [PMID:36847624]
- Ixekizumab for treating ankylosing spondylitis. (Immunotherapy, 2019) [PMID:31530049]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (2023) pubmed
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (2016) pubmed
- Ixekizumab for treating ankylosing spondylitis. (2019) pubmed
- Ixekizumab for the treatment of psoriasis: up-to-date. (2020) pubmed
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. (2017) pubmed
- Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. (2022) pubmed
- Ixekizumab in the treatment of psoriatic arthritis. (2021) pubmed
- Ixekizumab for the treatment of ankylosing spondylitis. (2020) pubmed
- [Ixekizumab]. (2019) pubmed
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. (2017) pubmed